The phase III EMERALD study found that when used as a monotherapy for the treatment of ER+/HER2- advanced or metastatic breast cancer, elacestrant significantly improved progression-free survival in the overall population and in patients with tumors harboring estrogen receptor 1 mutations, compared to the standard of care.
Up to 80% of adolescents and young adults with cancer are affected by reduced fertility after treatment—but only 50% received oncofertility counseling and preservation options prior to beginning treatment.
